Crystalline forms of a Bruton's tyrosine kinase inhibitor
AssigneePharmacyclics, Inc.
InventorsNorbert Purro, Mark S. Smyth, Erick Goldman, David D. Wirth
Life of this patent
Estimating the term…
Abstract
Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Claims29
A pharmaceutical formulation for oral administration comprising:
- (a) about 40 mg to about 200 mg of 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one;
- (b) about 40 wt % to about 50 wt % of one or more diluents;
- (c) one or more disintegrating agents;
- and
- (d) about 0.2 wt % to about 1.0 wt % of one or more lubricants.
Dependencies are inferred from the claim text.